Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...

Alterity Therapeutics (ATHE) announced that the last patient in the ATH434-202 Phase 2 trial has completed the study. The ATH434-202 is an open ...

The mammalian immune system is an evolutionary wonder. It's capable of recognizing and destroying cancer cells, and it can ...

Researchers examine space station experiment samples brought back by the Shenzhou XVIII spacecraft at the Technology and ...

A study from Cornell researchers could enable a quantum leap forward in identifying and deciphering cancer-driving genetic ...

Alterity Therapeutics (ASX:ATH, NASDAQ:ATHE) has announced the completion of its last patient visit in the ATH434-202 open-label Phase 2 clinical trial for multiple system atrophy (MSA), a rare and ...

Apitegromab, a fully human monoclonal antibody, works by selectively binding to the pro- and latent forms of myostatin in order to inhibit myostatin activation.

Yoda Therapeutics Inc. (YODA), an AI-driven company that focuses on Central Nervous System (CNS) drugs, today announced the dosing of the first patient in the Phase 2 trial of YA-101 for Multiple ...